Latest / Diagnosing Dx / Could a 10-Minute Test Stop Unnecessary Antibiotic Prescribing? Paul Kase, CCO - Lumos Diagnostics

Transcript

Could a 10-Minute Test Stop Unnecessary Antibiotic Prescribing? Paul Kase, CCO - Lumos Diagnostics · Diagnosing Dx

• David Filby: Welcome to the show this week, Paul. How are you? Paul: I'm excellent, David. How are you? David Filby: Yeah, very good, thank you. Very good. Where in the world are you? Paul: I'm in Bay Head, New Jersey right now. We live in Naples, Florida, but to escape some of that tremendous heat, we spend our summers here in New Jersey on the shore here. So how about yourself, where are you located? David Filby: I'm in London for the summer and it's been a brutal summer. Paul: Yeah, I was gonna say you're not escaping heat going there. Right. David Filby: Yeah, now we just need to figure out the invention of aircon in the UK. It's just utterly ridiculous. Paul: Okay. David Filby: But there we go. I'm super excited to get into this today because there's some really significant milestones that we're gonna be able to share about Lumos today. And I think if you didn't know anything about Lumos you'd probably think that these things weren't happening and you weren't as advanced as you are. So that's always exciting. But before we get to do that, it'd be great to know more about you and your background and career, what you've been doing, if you could take us through sort of what you've done up until this point and we'll go from there. Paul: Yeah, of course, David. Well, first of all, thanks for having me. You know, it's not bad to sit back and sip a little coffee and talk about what I live and breathe every day. So I appreciate that. My background, just a quick background of mine, 30 years in healthcare, 20+ years in just the actual rapid diagnostic point-of-care testing space. A majority of that with a company called Quidel, which is now QuidelOrtho but Quidel Corporation, where I just basically got into learning the market, learning the players, distributors, manufacturers, and got some commercial leadership experience under my belt. And that was about 12 years. And for folks, you know, who are listening to this and understand the startup side, when you get that startup bug, and you want a little skin in the game and you want to increase the frenziness of your professional life, well then you jump. And so I went into a startup that's back in 2012. And at that time it was called RPS Diagnostics. And the reason I bring that up is because that's when I was first introduced to FebriDx which we'll be discussing today. And it was just a concept at the time. So as you can imagine, this journey for me with FebriDx has really been since 2013 till today. So a 13-year journey around that product. We with RPS Diagnostics commercialized rapid point-of-care testing in the eye space. So we were calling on ophthalmologists and optometrists. Long story short, sold those two assets serendipitously back to Quidel Corporation, what became Quidel Eye Health, found everybody a home. And then did another brief stint there. But as I said, once you have that waking up awfully early with a cup of coffee and then maybe late night a glass of wine, that's 16 hours in between there. You're just used to this frenziness and this activity. So COVID comes, I find my way to Lumos Diagnostics where I am now, 6 years. And at that time, Lumos had acquired the IP for FebriDx. And so it was a reunion for me, if you will, with FebriDx and then my journey began with FebriDx at that time. So with Lumos now 6 years and became chief commercial officer last year. David Filby: Right, so now chief commercial officer. So that's an interesting title in itself, right? Because that would indicate some pretty important and significant commercial milestones and goals at the moment. You know, a lot of startups wouldn't even have a chief commercial officer unless it's necessary. Why was the transition promotion to chief commercial officer necessary for Lumos at that time? Paul: I think back to kind of wearing a lot of hats, David, with a startup. So at that time we needed much more of a presence around marketing, our international sales and direction, website technical support, customer support. And we were anticipating at that time and it has come to fruition, the CLIA waiver grant, which we'll get to in a second around regulatory for FebriDx. And so it really became pivotal to have a leadership component around those different departments. It's been a wild ride. Right? And understanding that, the leadership team, everyone. We try to stay in our lane, right? It's important to stay in your lane. But at the same time, as I said, with a startup, you're involved in so many activities, especially for me on the investor relations side, the public relations side, and obviously working on driving our share price up. So yeah, David, it was more out of necessity, but the same time as the company continues to experience success and milestones, it makes sense for everyone to take on more accountability. Is the best way to put that. David Filby: Fantastic. I love anybody that has the startup bug, if I'm honest. I've been very fortunate to be in and around startups for a long time and also be part of a startup that grew from 20 people to 450 people whilst I was there over ten years, and that was incredibly exciting, but it always took me back to the start, you know, that bug for it. Paul: Yeah. David Filby: So, who are Lumos today and the history, because you've taken us into a bit of an insight there already, but what does it Paul: Yeah. David Filby: look like today? Paul: So just a quick history on Lumos. Went public in 2021 and we received our first FDA clearance for FebriDx in 2023. That clearance though did not include a CLIA waiver grant. It was basically what they call a moderately complex test. And so your market is basically truncated at that point. In other words, instead of 300,000 targets, you're limited to a fraction of those, probably about 15,000. And so then the work continued to produce another clinical trial to get to the CLIA waiver grant. And we then achieved that this past March. So that CLIA waiver grant now unlocks a tremendous opportunity in the urgent care and primary care space where these CLIA-waived labs, these doctors' offices, right, are performing other rapid point-of-care tests like COVID, like flu, like strep, and now FebriDx can be part of that workflow. Whereas the previous label didn't allow us to do that. And so where Lumos is now is we just announced our annual report as well as our end of year results. Our fiscal year goes from July to June. So we just finished up our fiscal year 2026. Happy to report that we did 13.2 million and grew 6% and FebriDx as of the last year was a growth of 875% So tremendous growth and trajectory there and we'll continue that with our execution and our go-to-market strategy. So if I had to describe Lumos, one we have our service side of our business and then we have our commercially branded side and that commercially branded side, there's just a lot of focus and in a good way. Myself and my team we're in the crosshairs, right? Because now it's time to execute. Right. Now it's time for our investors to see quarterlies, positive results on quarterlies, and to execute on our go-to-market strategy, which I believe is extremely sound. And so that's really where we are. We finally have the license to hunt, David, and then it's now about the execution. And what's really interesting about that is we worked so hard to get this, it was a heavy lift and we got to this CLIA waiver grant. And we all celebrated for one day because we realized, okay, now actually another chapter of serious work, you know, begins. And so, that's where we stand right now. David Filby: That's so awesome. So we're obviously gonna get knee deep into the CLIA waiver side because it's such a significant milestone and foundation in itself. Just give us an insight into the science and the unmet need of what FebriDx is solving. Paul: Yeah, so sometimes when you introduce a product, especially a novel product like FebriDx, and we'll talk more about the go-to-market strategy and some of the important pillars I believe you have to focus in on. But as far as the chemistry of the test, we have two biomarkers, two protein biomarkers. One's called C-reactive protein or CRP, and the other is MxA, which is myxovirus resistance protein A. And at the end of this, David, I'm gonna have you say that three times fast, And we'll see how that goes. So with MxA and CRP, CRP is non-specific and a biomarker for inflammation. It's fine, but you need two, in this case, two biomarkers to make the magic happen. So along with CRP, you bring in MxA, which elevates with a viral infection. Okay, it does not elevate with a bacterial infection. So from a host immune response test that has two biomarkers that is disposable, that's one drop of fingerstick blood that results after 10 minutes with no instrumentation and is in the CLIA- waived setting, that unmet need of differentiating a bacterial from, say, a non-bacterial infection at 99%, meaning ruling out, which we'll talk about in a second. That to me is the value proposition. That to me is now our unmet need going into these doctors' offices because quite frankly, it doesn't exist in the rapid point-of-care testing market. And so we're really proud of that. So we've introduced it and thanks to David yourself and this popular podcast, and we're just trying to get awareness and education out there that the product even exists, David. That's what's interesting. David Filby: Let me flip it on the unmet need. I'm a patient and I walk into one of these CLIA-waived settings. What's the current standard of care on the symptoms I'm walking in with versus what FebriDx changes in terms of that patient experience? Paul: Yeah, it's a great question. Okay. So, David, you walk in and right now, depending, let's just call it urgent care XYZ. Okay. That is a growing market, right? And from a service standpoint, they're providing a lot of solutions outside of just diagnostic testing, right? So you walk in and let's just assume their current workflow, is and again you're walking in with acute respiratory infection symptoms and their current workflow most likely is going to include a battery of rapid point-of-care tests around COVID around influenza potentially RSV and then on the bacterial side a strep A test okay so it's about up until FebriDx's launch here in the CLIA-waived setting it's about ruling in. So in other words if you went in and they're gonna try to figure out do you have COVID? Do you have flu? And so they're ruling in the antigen, right? That's really important. So that's what's occurring now. The difference now, David, is you walk in and signs and symptoms overlap right between bacterial infections and viral infections or non-bacterial. Because David, you might be clamoring for a broad spectrum antibiotic, right? You might be saying, hey, listen, I really feel like I want, you know, just name the antibiotic. If they're not able to provide a solution to that need, well, David, how long does it take them to just hit a button? And it doesn't mean the doctor is doing anything wrong or the nurse practitioner is doing anything wrong. It's just that if there's not a tool to say, no, you don't need an antibiotic and it takes 20 minutes to educate that patient like yourself on why they're not going to give you one. They might and they've admitted this and it's okay. It's because they don't have the tool. Hit a button and it goes to CVS or it goes to Walgreens and you get your prescription and suddenly now it's a contribution to the overprescribing of antibiotics. And so that's what's currently occurring in many instances. And so where FebriDx comes in is okay, along with the other workflow that I'm already doing with testing, I'm going to incorporate FebriDx I'm now going to show the patient why at 99% accuracy ruling out bacterial infection, then we can run these other tests to rule in. And now I'm in a way practicing much better antimicrobial stewardship. Does that make sense? David Filby: Yeah, complete sense. Amazing. So let me take it back one second. So when you rejoined Lumos, where was FebriDx in terms of development and were you guys always planning to go down the clinical trial route to gain the CLIA waiver? Was that always fundamental to the success of the product? Paul: Always fundamental. So it was CE marked. So we have trademarks on FebriDx in US, in EU and UK. Okay. And so in many instances until clinical trials are complete in the US, a lot of US companies producing these types of tests will start working in the UK. A lot of times you can kind of get your bugs out a little bit, get a lot of voice of customer, things like that. So when I rejoined or joined Lumos basically and re reunited with FebriDx, there was nothing in the US other than us planning, right, to get the clinical trials in place and to move that forward. You know, David, to me, the US has always been when it comes to point-of-care diagnostics, and we'll talk about healthcare economics in a second. It's always been about that's where the volume is, that's where the demand is, that's where the reimbursement is, okay, in the US. And so I can't imagine there's many, especially on a startup side, companies not focusing on eventually getting into that US market. Rarely do those folks, you know, stay international, if that makes sense. It was always David Filby: Right, that makes sense. I mean clinical trials are expensive, right? Was there capital raised to fund that and how long did that take to get you through to the CLIA waiver? Paul: Multiple raises over the past 4 years. The last raise we just did, which is in the public domain, of course, is when we announced our CLIA waiver grant at the end of March. We did a raise to basically capitalize the company and help us with our operations. And that was just done this past March. And so currently, right now we have the money we need and we're executing and using those resources primarily into my team's goal of commercializing the product. David Filby: And you mentioned reimbursement there. Talk me through that. How does reimbursement for a product like this work? Paul: Okay, so first if you don't mind, I'm gonna step back and say, any go to market strategy with a rapid point-of-care test, or especially a novel one. Okay, novel is a great word to say. We can use the word unique, we can use whichever, but when you're going after the US market with a novel test, you better have three pillars in mind. You gotta have three. One of them is clinical utility. The other, David, is operational efficiency. And the third, which we'll talk about, which will address your question, is the healthcare economics. Okay. None of those are sometimes fully baked with the launch, but they have to be in your sights. And so on the standpoint of that, so I'll just use FebriDx and clinical utility, that's your unmet need that you've gotta differentiate yourself. Operational efficiency is, Is this changing physician behavior? Can it be put into an existing workflow? Is it providing an answer that is not being addressed? Can it improve the patient experience? There's so many factors around operational efficiency, and luckily FebriDx is tackling those. And then to your point, there's the healthcare economics. And you have to make sure that you have your clinical lab fee schedule. CPT code or in our case a PLA which is in that CPT code family. And you've got to be able to launch and get utilization moving of the test so you can continue conversations with payers to make sure that you eliminate as best you can the denials of the test. So that's how reimbursement in the US works. It's extremely complicated, but in layman's terms, you sell the test, they use the test in the market, right? Again, urgent care XYZ. They then place a claim for that test, name the private payer, Medicare, could be Medicaid, government, state, and then there's obviously many private payers. You have to prove that economic story, but it's never perfect, not even close on the front end. It's a 2-3 year process, David. And that's why you need consultants. That's why you need in our case, we hired a company called PRO-spectus out of California, who literally holds the hand of our customers in that first claim process, demonstrating medical necessity. By the way, medical necessity is key. And that's part of your clinical dossier. And then on the back end, they hold the hand on the denial. Okay, let's see if we can get a hold of the payer and try to get this done. And it's an awfully complicated process. I'm just trying to simplify it. That if you don't have a lot of attention on that healthcare economic piece, I'm sorry to say, but in the US, a lot of times care does follow cash. I'm not saying that's all the time, but so you've really got to make sure you're staying on top of that. We also partner with a company called AcuityMD, I speak fairly highly of them too. And that's where we get our claims data. That's where we find out which physicians are actually using the test. And then we get reimbursement information on the back end from that relationship too. So it's that alone, as you can imagine. Remember, I talked about that 16 hours in between, you know, 5 a.m. coffee and a glass of wine. That's just one factor that's so critical besides the clinical utility and the operational efficiency. And it has to be very very much prioritized. David Filby: Does that mean that because of the way you're bringing this product to life and that the CLIA waiver was so pivotal to ultimately the access to the product and its adoption, does that mean that the reimbursement journey almost I'm sure it's started and there's a lot of planning before, but once the CLIA waiver is in, does that mean okay now we're aggressively approaching the payers and Medicare, Medicaid and everything in between. Because it's sort of the start of phase two almost. Paul: Absolutely. So at the beginning, and again, any startup executive who's listening to this podcast is hopefully nodding. You have to get out ahead of that and get your code and then you get your reimbursement. We went on the clinical lab fee schedule in January 2025, at $41.38 per test. That's the recognized reimbursement. Now, David, reimbursement doesn't equal coverage necessarily. Reimbursement is you have to have it. But to your point, CLIA waiver then is the starting point to getting adoption and utilization. And once it's utilized and the claims go through, it bolsters those conversations with private payers to get coverage policies. Does that make sense? David Filby: Yeah, completely, yeah. Paul: Yeah, it's I mean it's interesting how this works. You can't get coverage policies until you get a lot of utilization. And it doesn't mean it's not being reimbursed, it doesn't mean they're not gonna pay it, but to get a coverage policy, you need a lot of claims. But it's hard to get a lot of claims if you don't have a CLIA waiver. So the CLIA waiver starts that process, as you've accurately said. David Filby: Yeah, so in a way it's back to front compared to other diagnostic testing where we would see an LDT be signed off because people want to get access to their test, generate data as they go, but reimbursement is, you know, a longer play down the road, but they're able to generate revenue and data as they go. Not easily, but you know, we see a lot of people choose the LDT routes and obviously one of the benefits of FebriDx is that it's you know a disposable 10 minute test on site. The LDT setup is obviously not relevant. So talk to me about commercialization since March then. What's the plan there? I noticed a few partnerships have been signed and so forth, but what does the commercial strategy look like? Because it feels like everything now is about how do we get this out, right? Paul: So just to give you an update, I'll tell you where we are as far as traction. We'll have another update coming actually at the end of next week. But right now we have 350+ sites in evaluation with 170 ordering sites, 24 states, and of those sites I mentioned, it represents about a million ARI visits, which is sometimes we gauge the ARI visit obviously to what we can expect from a standpoint of FebriDx revenue. So you first have to look at, okay, well, of the 80 million, David, patient ARI visits a year, we have some source data around all this, but say right around 80 million, 68 million, 65-68 million are in the primary and urgent care space. And so first you have to know where you're going and then David you have to stay patient and focused because the distractors can't wait to distract you. Right. They wanna push you into say a government spot and there's nothing wrong with exploring some of those, but we are dead set into this urgent care and primary care space. And of the urgent care, 14,000 sites. For urgent care in the US and it's growing. And then you have another 160,000 sites in primary. But of those 14,000 sites, the top 100 urgent care organizations represent just under 5,800 of sites. Now imagine 5,800 sites, right? And there's a lot of ARI going through each one of those. So it's for us, and again, some in the public domain, many of our webinars, and investor decks have talked about, well, that's so stay focused, right? Where are we going? So WellStreet, okay, to talk about where we are and where we're going. WellStreet Urgent Care got a head start. They wanted to pioneer and they even adopted FebriDx in one site as a moderately complex product. This was at the end of last year in 2025. So they got a head start around it and looked at it and Dr. Brian Bobb is one of our key opinion leaders. Oversees their clinical. And he's basically, the results we're seeing there are very positive around lowering prescription rates and things like that. Okay. Well, they are now in 44 sites. FebriDx is in 44 of their sites and looking with the expectation to expand to their 170 sites. Now they are one of the top 10 of that hundred urgent cares I was talking about. But as you can imagine, you take the recipe that we've developed with WellStreet and we duplicate it right as best we can to other urgent cares. And so that includes, to your point, focus on reimbursement through PRO-spectus our consulting resource. They've been doing a great job working with AcuityMD and monitoring those claims coming through. And then making sure that we're basically looking at all the leading indicators that WellStreet can give us and that is prescription rate drops, things like that. And then you find out, for example, with reimbursement, David, where your holes are. And there are holes. There will be holes. But then you can work on patching those, right? And as I said, that's a multiple-year process. So that's where we're living. That's where we're working. That's where we've directed as we worked with PHASE Scientific, and PHASE Scientific is an exclusive distributor. They signed a $318 million distribution deal with us to sell FebriDx, and they work with sub distributors, Henry Schein, McKesson. And so between PHASE, our distributor reps, a company called MTMC, which is a contract sales force. And our own sales force, we are doing a massive, very focused campaign into the urgent care space. David Filby: That's interesting. So it feels like you're using a variety of commercial strategies to ultimately drive adoption. Is that by design, is that like very intentional? Paul: So I think it's understanding as a startup where we don't have resources available to us like internally. So I think it's about saying, okay, well, back to those three pillars, right? Who can help us on the reimbursement side? Back to adoption and awareness, who can help us create that in the field? And that's your 2000+ distributor reps, right? And then ultimately staying focused and letting the product basically speak for itself on the clinical side, which I'm happy to report is doing extremely well. So then it's really become a matter for us of making sure we customize to the workflow, to the physicians of that particular practice and then ultimately staying on top on the reimbursement side. And again, all this started basically April 1st for us. But we're just thrilled with the leading indicators and what they're showing so far. David Filby: Amazing. Obviously listed in Australia and you mentioned CE Mark. So there's an international feel throughout the company and product, right? What does that mean to the future, is this something that you're like how do we take this global as fast as possible? And I guess Paul: Yeah, yeah. Yeah. David Filby: back to that temptation question as well, isn't it? You know, sometimes it could be really tempting to do far too much too quickly, Paul: Yeah. David Filby: How does the international play come into it all? Paul: Well, we're in 19 countries with FebriDx now as far as registrations. David Filby: Wow. Paul: Yeah. It doesn't mean there's a ton of volume there, David, right? And so David Filby: Yeah. Paul: back to your point, I don't find it a distraction. We just put on, for example, Romania and a great distributor there. And so we'll continue to explore those opportunities, but I will say where we want to focus and where we feel like the revenue is for the next 2 or 3 years, and then we can take once we become established and distribution it's not necessarily as novel. We've created the market for ourselves, right? Then I think we can parlay a lot of the lessons learned to the UK and other countries, right? But we've isolated the US really because of, as I said, where we feel like the volume opportunity is and where we can scale quickly, right? David Filby: Yeah. Yeah. That makes complete sense. Yeah, obviously the biggest opportunity, and probably always will be. And what about future development? Is there the ability to open newer markets in terms of patients or things that FebriDx can do beyond this? Is there further development planned and where could it go? Paul: I want to throw out another resource by the way that I forgot to, and that is CG Life. We've partnered with CG Life to help us get that education awareness out from a marketing standpoint. Really excited about those campaigns and the analytics around those. And so with that increase in exposure and awareness that again a company like CG is doing for us too. And again, thank you for allowing me the time to talk to you, David, because all these help. It's then about, all right, well, what other markets? Well, I'll tell you, there's quite a few. In other words, within the US alone, there's correctional health, there's employee-based work site health, there's cruise health, university student health. I mean, the list actually goes on. Perfect example too of Texas A&M, you know, uses FebriDx. and we've used their name because they've allowed us to put out some PR around Texas A&M. And, there's a different leading indicator around why a customer in a certain market's going to adopt FebriDx. And what's interesting about student health is that a student comes to a student health center feeling really poor and they leave without an antibiotic. Right? They many times do. Well, that student's gonna call the parents, and the parents then call the student health center and say, why did you not give my child an antibiotic? Little things like that that FebriDx solves from an even an administrative standpoint is interesting. It's also helping physicians with Yelp reviews. So a patient is feeling more satisfied and the reviews come through. So it actually is interesting. We're gonna see where our next big market is, but I feel as though FebriDx, it's a $1 billion total market right now, David. Like it's actually a billion plus. And right now, and I don't mind saying this because it's in the public domain, that average cost per test to a consumer, to the actual physician, say $25 to $30, right? Well, you know, if you have 80 million patient visits and you're looking at you know, it's a rather large opportunity. So we're just gonna continue to stay focused in the urgent care spot. And we're gonna see when we can move and extend and expand into some of those other markets. David Filby: What about pediatrics? Paul: So our age claim on FebriDx right now is 12-64. The reason being is actually internationally we have the claim for pediatrics, but it's a long story, but I'll truncate by saying during COVID, when we were running the first clinical trial, okay, called the DISRUPT Study, we didn't get enough children during COVID. into those offices. So it had nothing to David Filby: Make sense. Paul: do with it not being accurate for kids. In fact, it's internationally that's where it's used. So we have a funded study right now through BARDA and the government to actually lower that age claim. But we wanted to take the 12-64 with the CLIA waiver and then get our clinical trial, which is going on right now for pediatrics, and come back to the market with the lower label. David Filby: Makes complete sense. I'm a dad of two young children, right? I'd tell my wife this and she'll be like I'd love that. I'd love that like because you know, going to the doctors and just walking away with you're getting prescribed antibiotics and you don't actually know. We've been there so many times. But that's super interesting and incredible that you've got that funded trial ongoing. How long do you think that trial takes? Paul: It's tough. It's a great question. It's tough to say because pediatrics and getting the number, it's a big number of getting positives into that study. That's not simple to do. It just takes time. David Filby: Sure. Paul: It's a lot easier on the obviously the non bacterial viral side. That's not the issue. It's getting those sick kids. And so, yes, that's ongoing. I will say BARDA also funded the CLIA waiver study at the 12-64 So we appreciated David Filby: Fantastic. Paul: the relationship and partnership we have with them too. David Filby: Yeah. What other future milestones should interested parties be on the lookout for with Lumos and FebriDx? What's coming up in the future that we should all be excited about? Paul: I think it's about our future quarterlies and our revenue growth. David Filby: Yeah. Paul: And again I'm not trying to oversimplify this, but I find that when you have a test like FebriDx that doesn't have in our market, in our CLIA-waived market, we're not looking over our shoulder at competition right now. We have a strong IP position in the US. Now that's not saying that we'll never have competition. In fact, I have a feeling host immune response tests will be coming down the pike here soon and coming right at us and that's fine. That's what happens when you pioneer a new market. And so I think what I'm gonna ask you and our investing community to look for is a tremendous growth rate. Over the next two or three years, like tremendous growth rate. Based on urgent care partners and based on the actual unsolicited demand right now. Like it's a Push + Pull + Prove strategy, David. So a lot of times we were thinking, okay, we're gonna be pushing for a while here until we can get a pull. Well we're actually seeing quite a few folks coming to us before we even reached out to them first. And we find that very positive and something that we find very encouraging, to be honest with you. David Filby: Makes complete sense. It feels like everything has lined up and you're now at this tipping point of raising awareness and ultimately commercial traction and adoption. And I'll tell you one of the things I love is that the commercial strategy you've spoken about and sort of using different ways to do that, I think is very mature. And you know, anybody right now who's got a novel diagnostic test and they think they're gonna build a 400 man sales team over the next 10 years, it's just like really come on, like be prepared to give something away, whether it's in revenue or profit or equity to drive adoption of that test. I love that. I love the simplicity of it, but I love the necessity of it. I love its impact on clinical workflows. And I think it's exciting that we can sit here today and go watch the traction publicly grow. Paul: Yeah. Yeah. Yeah. David Filby: Quarterly being able to go, look at it. Like look at how well it's been adopted. That's actually really exciting for me. I think I'm gonna be following along with the quarterly financial reports just to sort of see the journey from here and see how it goes, you know? Paul: Thank you. Thank you. We have our website and you can always click on subscribe and get our PR and you know we send out a PR usually once a month, not to mention the ASX announcements, but our EDM David Filby: Yeah. Paul: PR comes out quite a bit and we'll continue to provide exposure to our commercial traction via PR and LinkedIn is obviously a big resource for us as well. But you know, I would say, David, and I appreciate your feedback. I really do. and I agree with it. It's a very exciting time. There's still so much to do, right? There's still the days. I said those 16 hours, it just shifted into execution. And along with that, I would caution, I would just say to any novel, any manufacturer, and I say, bring it on, whether that's in women's health, whether that's UTI. I mean, there's a lot of markets that novel testing can go into and a lot of companies are working on those. And I'm a huge fan of all of them. I would say where a startup goes south is if you don't stay patient and focused. And the patience is the hardest part because it's years of building. You gotta build and you gotta build it correctly. And you almost can stub your toe, David, but if you make a mistake that you can't recover from, it's you know, sometimes you only get one chance at that one. So I will say that based on my experience and all the awesome leaders and mentors I've had in my life, you can peer around a corner or even another corner and just make sure that commercial strategy is sound and so far so good. Lots to do, but we're really excited. Yeah. David Filby: I assume you're now the busiest man at Lumos. Paul: Well, I'd say the accountability, you know, so there was accountability, then it went over to actually regulatory and clinical affairs and manufacturing, by the way, is being held accountable too. But yeah, I think but myself and operations in Carlsbad, a gentleman by the name of Anthony Favaloro, he's so good at what he does. The two of us, yeah, we're being pulled on quite a bit, but it's all good. It's all good. Yeah. David Filby: Fantastic. Paul, thank you so much for coming on and sharing the story. It genuinely is super exciting and to get to talk to you now at this phase. I'm excited to talk to you again in 12 months' time and get you back on and go how's the last 12 months been since we talked about this and see the progress, but even better. I love that we can follow this journey now in public and see how the progress ramps up and I can't wait to use the tests, you know? Like that is in a way that I can't wait to go into an urgent care or my kids to go in and be like, okay, FebriDx it's like great, that's the first thing. I'm happy with that, you know, and now we move in the direction we need to move. Paul: Yeah, we have a slogan, FebriDx First, and it's not always gonna be first in everyone's workflow, but it is gaining traction that way. And I would love it to your point, David, it's probably 3-4 years from now, maybe 5. I'm hoping it's sooner than that. But someone said, did you get FebriDx'd? It would just be perfect, right? Did you get FebriDx'd before you take that antibiotic? So anyway, it's been a privilege, David. I can't thank you enough. Congrats to all your success too, that you're having. And yeah, let's definitely stay in touch. David Filby: Perfect, Paul. Thanks a lot.